ESMO 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ESMO 2022 Conference Coverage

Breast
Lung
GI
GU
Head and Neck
GYN
Sarcoma
Hematology

Playback speed

10 seconds

ESMO 2022 Initial Results From the Phase 3 SPLASH Study: Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in mCRPC

By ESMO 2022 Conference Coverage FEATURING Aaron Hansen

280 views

September 21, 2022

Comments 0

ESMO 2022 on the JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance …

ESMO 2022 Conference Coverage

J. Aragon-Ching

248 views

ESMO 2022 on the Results From the PREVAIL Prospective Cohort Study: …

ESMO 2022 Conference Coverage

P. Grivas

148 views

ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Inj…

ESMO 2022 Conference Coverage

J. Avitia

43 views

ESMO 2022 Initial Results From the Phase 3 SPLASH Study: Efficacy an…

ESMO 2022 Conference Coverage

A. Hansen

280 views

ESMO 2022 on the Phase 3 VISION Trial: Comparing 177Lu-PSMA-617 Trea…

ESMO 2022 Conference Coverage

A. Armstrong

182 views

ESMO 2022 on the Impact of TURBT and Intravesical BCG vs. Radical Cy…

ESMO 2022 Conference Coverage

P. Haddad

136 views

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Ben…

ESMO 2022 Conference Coverage

G. Sonpavde

134 views

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

ESMO 2022 Conference Coverage

G. Sonpavde

810 views